GABPB1 and stage 5 chronic kidney disease: However, a recent phase 3 study where the nuclear respiratory factor 2-inducer bardoxolone methyl was used for targeting diabetic nephropathy failed to improve the outcome of end-stage renal disease or cardiovascular mortality.